Department of Maternal and Child Health, Instituto de Medicina Integral Prof.Fernando Figueira (IMIP), Recife, Pernambuco, Brazil,Department of Obstetrics,Universidade Federal de Campina Grande (UFCG), Campina Grande, Paraíba,Brazil,Faculdade Pernambucana de Saúde (FPS), Recife, Pernambuco, Brazil.
Medicine (Baltimore). 2022 Mar 18;101(11). doi: 10.1097/MD.0000000000029059.
To determine the association between soluble FMS-like tyrosine kinase-1 (sFlt-1) and high-sensitivity C-reactive protein (hs-CRP) with maternal and perinatal outcomes in patients with preeclampsia (PE) with severe features.A cohort study was conducted on 100 patients, 60 with PE with severe features, and 40 healthy women in the third trimester of pregnancy. Admission serum levels of sFlt-1 and hs-CRP and clinical and epidemiological parameters were evaluated to quantify the predictive ability of adverse maternal and perinatal outcomes using hierarchical multiple regression and receiver operating characteristic curves.Compared to controls, patients with PE and severe features had significantly higher levels of sFlt-1 but not hs-CRP. sFlt-1 and hs-CRP proved to be reasonable parameters for the prediction of composite adverse maternal outcomes. However, we found no correlation between these 2 biomarkers. PE integrated estimate of risk scores were correlated only with sFlt-1 levels. Regarding fetal outcomes, unlike hs-CRP, sFlt-1 was strongly associated with birth weight and Apgar score < 7 at 5 minutes. Following multivariate analysis, maternal age, previous hypertension, sFlt-1, and hs-CRP levels remained independently associated with composite adverse maternal outcomes.sFlt-1 levels were elevated in patients with PE and severe features. Both sFlt-1 and hs-CRP may predict composite adverse maternal outcomes but do not correlate with each other and differ in perinatal morbidity patterns. These data support the hypothesis that the varied outcomes in PE may result from different pathogenic pathways.
确定可溶性 FMS 样酪氨酸激酶-1(sFlt-1)和高敏 C 反应蛋白(hs-CRP)与重度子痫前期(PE)患者的母体和围产结局之间的关系。
对 100 例患者(60 例重度 PE 和 40 例健康妊娠晚期妇女)进行了队列研究。评估入院时 sFlt-1 和 hs-CRP 血清水平以及临床和流行病学参数,以使用分层多元回归和受试者工作特征曲线量化不良母体和围产结局的预测能力。
与对照组相比,重度 PE 患者的 sFlt-1 水平显著升高,但 hs-CRP 水平无差异。sFlt-1 和 hs-CRP 被证明是预测复合不良母体结局的合理参数。但是,我们发现这 2 种生物标志物之间没有相关性。PE 综合风险评分与 sFlt-1 水平相关,与 hs-CRP 无关。关于胎儿结局,与 hs-CRP 不同,sFlt-1 与出生体重和 5 分钟 Apgar 评分<7 密切相关。多元分析后,母亲年龄、既往高血压、sFlt-1 和 hs-CRP 水平与复合不良母体结局独立相关。
sFlt-1 在重度 PE 患者中升高。sFlt-1 和 hs-CRP 均可预测复合不良母体结局,但彼此不相关,围产期发病模式不同。这些数据支持这样一种假设,即 PE 中的不同结局可能是由不同的致病途径引起的。